DexCom, Inc. vs MGM Resorts International — how do they compare? DexCom, Inc. trades at $90.21 (market cap $33.79B), while MGM Resorts International trades at $43.92 (market cap $11.10B). The key difference: DexCom, Inc. is far larger — about 3× MGM Resorts International's market cap, and MGM Resorts International pays a 0.03% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | MGM | |
|---|---|---|
Market Cap | $33.79B | $11.10B |
Sector | Health | Consumer Cyclical |
52-Week High | $89.53 | $50.69 |
52-Week Low | $54.84 | $30.72 |
Enterprise Value | $33.24B | $38.40B |
Dividend Yield | — | 0.03% |
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $90.23, up 2.94% today and near its 52-week high, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.70 versus $0.61 expected, and raised full-year guidance. Revenue growth remains robust at 13% year-over-year, supported by G7 system adoption and international expansion. Profit margins improved, with net income margin reaching 20.12% in 2025. Analyst sentiment is overwhelmingly positive, with 80% buy ratings.
The outlook for DXCM is favorable due to sustained demand for continuous glucose monitors and strategic initiatives like 'Road to 100'. Key risks include competitive pressures, regulatory scrutiny, and valuation multiples above industry averages. The stock's current price is slightly above the consensus target of $88.65, suggesting near-term consolidation may occur before further upside.
MGM Resorts International trades at $43.94, up 1.34% on the day, with a bearish technical signal from moving averages. The company reported record Q2 2026 revenue but missed earnings estimates, with net income margin at 2.4% for 2025. Recent news highlights a pending shareholder investigation into a proposed acquisition offer and expansion of BetMGM's partnerships in Canada.
The outlook is mixed: analyst consensus is a Buy with a $51.14 price target, indicating potential upside, but risks include margin pressure, high debt, and acquisition uncertainty. Earnings growth in Las Vegas and digital segments offers opportunity, yet competition and regulatory scrutiny pose challenges for shareholder value.
Trailing returns across standard periods
Latest headlines on both assets
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →